RoboStrategy's portfolio is gaining real-world validation: its fourth- and fifth-largest holdings, Apptronik at 15% of NAV and Dexmate at 10%, are being used at Google. x.com 

RoboStrategy gives retail investors pre-IPO exposure to leading US humanoid robot makers, and its chart is coiled for a breakout. CEO Andrew Kang named Tesla Optimus, Figure AI and Apptronik his top three American humanoid plays from 112 startups; Figure AI and Apptronik are among its largest disclosed holdings. He cited Figure 03 robots sorting a quarter-million packages over 200 hours without a major glitch. Price has squeezed into a symmetrical triangle since July, with $29.50 as the trigger. … Show more

BOT is a poor way to own private companies because buyers pay 5-6x net asset value. Investing directly at current funding rounds through a platform like MicroVentures is a better option. The only reason to buy is a bet that retail keeps pumping it, which may well happen, but it remains a bad investment. x.com 

VCX's collapsing premium to NAV signals that AI euphoria is deflating. The Fundrise Innovation Fund's NAV is $18.97; its price peaked at $380, about 20x NAV, and is now ~$76, still a rich 4x. That premium assumed NAV would keep rising with a static list, but Anthropic has overtaken OpenAI, with Databricks close. Anthropic can justify some premium; OpenAI is less certain. Nvidia, up only ~4% in six months, sends the same signal. This is not a call for the story to end. x.com 

It is far too early to invest in robotics, and ETFs such as BOTZ and ROBO are marketing wrappers full of legacy industrial firms and unprofitable startups. Teradyne's robotics segment brought in only $89M and cut 400 jobs, while ABB is spinning off its 12%-margin robotics unit. Humanoids still cost over $200k versus the $50-75k needed for mass use, a level projected for 2050. AI infrastructure spending is crowding out robotics capex; the alpha lies in the AI supply chain. x.com  x.com 

BOT, the robotics investment vehicle, looks built to capture dumb money riding robotics hype rather than to reward investors. It came to market at 5x NAV, still trades around 3.5x, charges a heavy ~3.6% annual fee and recruits crypto Twitter influencers, much like a Chamath-style SPAC. Toxic vehicles chasing robotics hype are likely to leave retail badly hurt, though such schemes can run hard until the music stops. x.com  x.com 

XPeng's $900M robotics raise is a huge vote of confidence from major players, implying either its humanoid tech is the real deal or a deluge of humanoid investment is coming. Per @wallstengine, the round valued XPeng Robotics at $6.3B+, led by IDG Capital with Tencent and Alibaba, to scale toward IRON mass production by year end and deliveries in 2027. It also offers a favorable valuation comp for XPeng, which had looked cheap at under 1x; its robots' relative strength is dexterity. x.com  x.com 

The Fundrise Innovation Fund looks wildly overpriced, trading at a premium to NAV never seen before. The listed fund offers access to private companies investors want but cannot otherwise own, and its price went parabolic in just four days. x.com  x.com 

The closed-end fund BOT is ridiculously priced against its NAV of $7.50, with buying driven by a longtime bitcoin promoter on X. A premium to $10 or even $15 might be defensible, but not the current price. x.com 

The labor-shortage case for robots is easy, but BOTZ and ROBO are the wrong way to own it, while humanoid pure plays KOID and HUMN hold it directly. Rich countries are running out of workers, so demand is a demographic fact, and the market is forecast to grow from $153B to $365B by 2030 on that alone. BOTZ and ROBO have lagged the S&P since launch, and BOTZ is mostly Nvidia and Japanese industrials, half outside actual robots. ARKQ gets there through Tesla, if you trust the driver. x.com